50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:VYGR

Voyager Therapeutics - VYGR Stock Forecast, Price & News

$5.57
-0.37 (-6.23%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.37
$6.19
50-Day Range
$5.57
$7.47
52-Week Range
$2.46
$10.60
Volume
169,163 shs
Average Volume
165,426 shs
Market Capitalization
$215.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
25.7% Upside
$7.00 Price Target
Short Interest
Bearish
3.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
-0.12mentions of Voyager Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$3.93 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.70) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

261st out of 1,080 stocks

Biological Products, Except Diagnostic Industry

39th out of 172 stocks

VYGR stock logo

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Stock News Headlines

Voyager Announces CFO Departure
Voyager Seeks to ‘Unwind’ Alameda Loan
Voyager Therapeutics Appoints Peter Pfreundschuh As CFO
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings
8/04/2022
Today
9/24/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+25.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-71,200,000.00
Net Margins
-193.48%
Pretax Margin
-193.48%

Debt

Sales & Book Value

Annual Sales
$37.42 million
Book Value
$2.50 per share

Miscellaneous

Free Float
30,145,000
Market Cap
$215.28 million
Optionable
Optionable
Beta
1.11

Key Executives

  • Mr. Robert W. Hesslein (Age 69)
    Sr. VP & Gen. Counsel
    Comp: $576.62k
  • Mr. G. Andre Turenne (Age 48)
    Advisor
    Comp: $600.3k
  • Dr. Alfred W. Sandrock Jr. (Age 64)
    M.D., Ph.D., Pres, CEO & Director
  • Dr. Krystof Bankiewicz M.D.
    Ph.D., Founder
  • Dr. Guangping Gao Ph.D.
    Founder
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Founder
  • Dr. Phillip D. Zamore
    Founder
  • Ms. Julie  BurekMs. Julie Burek (Age 47)
    VP of Fin.
  • Ms. Robin Swartz (Age 51)
    Chief Operating Officer
  • Ms. Michelle Quinn Smith
    Chief HR Officer













VYGR Stock - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price forecast for 2022?

2 Wall Street research analysts have issued 12 month target prices for Voyager Therapeutics' stock. Their VYGR share price forecasts range from $6.00 to $9.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 25.7% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2022?

Voyager Therapeutics' stock was trading at $2.71 at the beginning of 2022. Since then, VYGR stock has increased by 105.5% and is now trading at $5.57.
View the best growth stocks for 2022 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings results on Thursday, August, 4th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.06. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $2.50 million. Voyager Therapeutics had a negative net margin of 193.48% and a negative trailing twelve-month return on equity of 75.15%.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (2.14%), Price T Rowe Associates Inc. MD (2.14%), Federated Hermes Inc. (1.59%), JPMorgan Chase & Co. (0.74%), Connor Clark & Lunn Investment Management Ltd. (0.31%) and Goldman Sachs Group Inc. (0.28%). Insiders that own company stock include Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Matthew P Ottmer, Omar Khwaja, Robert W Hesslein, Robin Swartz and Rock Ventures Iii LP Third.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $5.57.

How much money does Voyager Therapeutics make?

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $215.28 million and generates $37.42 million in revenue each year. The company earns $-71,200,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How many employees does Voyager Therapeutics have?

The company employs 101 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.